Dr. Thomas Magee, MD

NPI: 1619183662
Total Payments
$1.2M
2019 Payments
$18.00
Companies
2
Transactions
6

Payment Breakdown by Category

Research$1.2M (100.0%)
Food & Beverage$68.51 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $1.2M 2 100.0%
Food and Beverage $68.51 4 0.0%

Payments by Type

Research
$1.2M
2 transactions
General
$68.51
4 transactions

Top Paying Companies

Company Total Records Latest Year
Romark Laboratories, LC $1.2M 2 $0 (2018)
Merck Sharp & Dohme Corporation $68.51 4 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2019 $18.00 1 Merck Sharp & Dohme Corporation ($18.00)
2018 $1.2M 2 Romark Laboratories, LC ($1.2M)
2017 $50.51 3 Merck Sharp & Dohme Corporation ($50.51)

All Payment Transactions

6 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
05/13/2019 Merck Sharp & Dohme Corporation ISENTRESS (Drug), PIFELTRO, DELSTRIGO Food and Beverage In-kind items and services $18.00 General
Category: INFECTIOUS DISEASE
11/15/2018 Romark Laboratories, LC Alinia Tablets 500mg 30 count bottle (Drug), Alinia for Oral Suspension, Alinia Tablets 500mg 12 count bottle Cash or cash equivalent $1,162,569.30 Research
Study: A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza • Category: Gastroenterology
11/15/2018 Romark Laboratories, LC Alinia for Oral Suspension (Drug), Alinia Tablets 500mg 30 count bottle, Alinia Tablets 500mg 12 count bottle Cash or cash equivalent $20,000.00 Research
Study: Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection • Category: Gastroenterology
09/18/2017 Merck Sharp & Dohme Corporation ISENTRESS (Drug) Food and Beverage In-kind items and services $16.04 General
Category: INFECTIOUS DISEASE
06/19/2017 Merck Sharp & Dohme Corporation ISENTRESS (Drug), ZEPATIER Food and Beverage In-kind items and services $18.00 General
Category: INFECTIOUS DISEASE
01/30/2017 Merck Sharp & Dohme Corporation ISENTRESS (Drug), ZEPATIER Food and Beverage In-kind items and services $16.47 General
Category: INFECTIOUS DISEASE

Research Studies & Clinical Trials

Study Name Company Amount Records
A Phase III Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide Plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza Romark Laboratories, LC $1.2M 1
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection Romark Laboratories, LC $20,000 1

About Dr. Thomas Magee, MD

Dr. Thomas Magee, MD is a Internal Medicine healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619183662.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Magee, MD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $18.00 received in 2019. These payments were reported across 6 transactions from 2 companies. The most common payment nature is "" ($1.2M).

Practice Information

  • Specialty Internal Medicine
  • Location Los Angeles, CA
  • Active Since 05/15/2007
  • Last Updated 07/08/2007
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1619183662

Products in Payments

  • Alinia Tablets 500mg 30 count bottle (Drug) $1.2M
  • Alinia for Oral Suspension (Drug) $20,000
  • ISENTRESS (Drug) $68.51

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Los Angeles